First-in-human study of IDRX-42 in participants with metastatic and/or unresectable gastrointestinal stromal tumors
Trial overview
Phase 1 (Dose Escalation) - Safety and Tolerability (Nature, incidence, and severity of any DLTs)
Timeframe: When participant completes 1 cycle (28 days) treatment with safety and tolerability assessment by investigators
Phase 1 (Dose Escalation) - Safety and Tolerability (Nature, incidence, and severity of any DLTs)
Timeframe: Approximately 18 months from first participant enrolled
Phase 1 (Dose Escalation) - Determination of the MTD and/or RP1bD(s) of orally administered IDRX-42
Timeframe: Approximately 18 months from first participant enrolled
Phase 1 (Dose Escalation) - C-QTc sub-study: QTcF - concentration response analysis
Timeframe: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
Phase 1b-Number of participants with TEAEs and with laboratory test results
Timeframe: Approximately 18 months
Phase 1b - Objective Response Rate (ORR) mRESIST v1.1
Timeframe: Approximately 18 months
Phase 1b - C-QTcF sub-study: QTcF - concentration response analysis
Timeframe: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
Phase 1 (Dose Escalation)- Number of participants with non-DLT TEAEs and with laboratory test results
Timeframe: 6 months
Phase 1 (Dose Escalation) - ORR per mRECIST v1.1
Timeframe: 6 months
Phase 1 (Dose Escalation) - Cmax; Maximum Observed Concentration of IDRX-42
Timeframe: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
Phase 1 (Dose Escalation) - Tmax; Time of First Occurrence of Maximum Plasma Concentration (Cmax) of IDRX-42
Timeframe: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
Phase 1 (Dose Escalation) - AUC 0-24; Area Under the Concentration-time Curve from Time Zero to 24 hours for IDRX-42
Timeframe: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
Phase 1 (Dose Escalation) - Duration of response (DOR) per mRECIST v1.1
Timeframe: 6 months
Phase 1 (Dose Escalation) - Time to response (TTR) per mRECIST v1.1
Timeframe: 6 months
Phase 1 (Dose Escalation) - Progression-free survival (PFS), per mRECIST v1.1
Timeframe: 6 months
Phase 1 (Dose Escalation) - C-QTcF sub-study: QTcF, heart rate, PR, QRS interval at baseline, post baseline and change from baseline.
Timeframe: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
Phase 1b- Duration of response (DOR) per mRECIST v1.1
Timeframe: 18 months
Phase 1b - PFS per mRECIST v1.1
Timeframe: 18 months
Phase 1b - Clinical benefit rate (CBR) per mRECIST v1.1
Timeframe: 18 months
Phase 1b - TTR per mRECIST v1.1
Timeframe: 18 months
Phase 1b - Cmax; Maximum Observed Concentration of IDRX-42
Timeframe: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
Phase 1b - Tmax; Time of First Occurrence of Maximum Plasma Concentration (Cmax) of IDRX-42
Timeframe: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
Phase 1b - AUC 0-24; Area Under the Concentration-time Curve from Time Zero to 24 hours for IDRX-42
Timeframe: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
Phase 1b - Overall survival
Timeframe: 18 months
Phase 1b C-QTc sub-study: QTcF, heart rate, PR, QRS interval at baseline, post baseline and change from baseline.
Timeframe: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
Participation criteria
- Phase 1
- 1. Male or female participants ≥18 years of age
- 1. Any prior exposure to the following investigational agents NB003 or THE-630 or bezuclastinib plus sunitinib combination (except for participants treated in Cohort 4 of Phase 1b).
- 2. GIST with no documented mutation in both KIT and PDGFRA genes.
- Phase 1 1. Male or female participants ≥18 years of age 2. Histologically or cytologically confirmed metastatic and/or surgically unresectable GIST 3. Documented progression on imatinib (Phase 1) 4. Documented pathogenic mutation in KIT OR any PDGFRA mutation other than exon 18 mutations, determined through local testing 5. At least one measurable lesion by mRECIST v1.1 for participants with GIST 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 7. Resolution of any toxicities from prior treatment(s) to ≤ Grade 1 by NCI CTCAE v5.0 criteria, or have resolved to baseline, at the time of first dose of study drug. 8. Willing and able to comply with scheduled visits, drug administration plan, laboratory tests, or other study procedures and study restrictions. Additional for Phase 1b Exploratory Cohorts 1. For Cohort 1, progressed on imatinib only (second line therapy) and refused or are ineligible for other standard of care (SOC) therapies. 2. For Cohort 2, progressed on both imatinib and sunitinib (third line therapy) or progressed on imatinib, sunitinib, and an additional agent (i.e., regorafenib or ripretinib) (fourth line therapy) or progressed on imatinib, sunitinib, regorafenib, and ripretininb (fifth line or greater therapy) 3. For Cohort 3, treatment naïve (first line therapy) and refused or are ineligible for other standard of care (SOC) therapies. 4. For Cohort 4, met the same criteria as Cohort 2 (third line or greater) and have also had prior treatment with investigational agents NB003 or THE-630 or a line of therapy of bezuclastinib plus sunitinib combination.
- 1. Any prior exposure to the following investigational agents NB003 or THE-630 or bezuclastinib plus sunitinib combination (except for participants treated in Cohort 4 of Phase 1b). 2. GIST with no documented mutation in both KIT and PDGFRA genes. 3.Primary brain malignancy or known untreated or active central nervous system metastases. 4. Has an active uncontrolled infection, including, but not limited to, the requirement for intravenous antibiotics. 5. Has significant, uncontrolled, or active cardiovascular disease.
Trial location(s)
Study documents
No study documents available.
Results overview
Study Results yet to be posted
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.